Our Platform

Traditional antibody discovery

The costly, time-consuming process of antibody discovery and engineering often ends once a ‘good enough’ drug candidate is found. Antibodies need to be translated from other platforms into mammalian cells and analyzed for function and the needed target interaction in its native state. If a candidate fails there are a limited number of other potential drugs to bring forward.

The OCMS solution

OCMS can with speed and certainty identify antibodies based on their ability to elicit a desired functional effect. OCMS eliminates the need for translation or the loss of potentially optimal drug candidates through lossless function first high-throughput mammalian analysis. This allows for the rapid generation of optimal best-in-class biologics that can overcome issues of safety, efficacy and convenience where other methodologies are forced to stop short.

Technology

The practical benefits of the OCMS rapid antibody screening system include faster identification of high-affinity, functional antibodies by screening 100,000+ natural variants in parallel, preserving native heavy-light chain pairings for optimal stability and specificity. It eliminates the need for recombinant expression (translation), reducing time and cost while enabling direct “function-first” screening of antibodies against complex targets. This accelerates lead selection and improves success rates for therapeutic antibody development.